NRAS and acral lentiginous melanoma: Among the patients without NRAS mutation, the ORRs of anti-PD-1 monotherapy were 23.9% for cutaneous melanoma and 13.7% for noncutaneous melanoma as follows: 12.1% in acral melanoma and 16.7% in mucosal melanoma.